Open Access

Downregulation of miR‑505‑3p predicts poor bone metastasis‑free survival in prostate cancer

  • Authors:
    • Yubo Tang
    • Bowen Wu
    • Shuai Huang
    • Xinsheng Peng
    • Xing Li
    • Xiufang Huang
    • Wei Zhou
    • Peigen Xie
    • Peiheng He
  • View Affiliations

  • Published online on: October 25, 2018     https://doi.org/10.3892/or.2018.6826
  • Pages: 57-66
  • Copyright: © Tang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The principal issue deriving from prostate cancer (PCa) is its propensity to metastasize to bone. To date, bone metastasis remains incurable, and therapeutic strategies are limited. Therefore, it is of paramount importance to explore predictive markers for bone metastasis of PCa. In the present study, we reported that miR‑505‑3p was significantly downregulated in bone metastatic PCa tissues compared with that in non‑bone metastatic PCa tissues, but there was no significant difference in miR‑505‑3p expression between PCa and adjacent normal tissues. miR‑505‑3p expression was inversely associated with serum PSA levels, Gleason grade, N and M classification, and short bone metastasis‑free survival in PCa patients, but had no effect on overall survival in PCa patients. Furthermore, upregulation of miR‑505‑3p suppressed the activity of TGF‑β signaling by directly targeting downstream effectors of TGF‑β signaling, SMAD2 and SMAD3, further inhibiting the invasion and migration abilities of PCa cells. Therefore, our findings unraveled a novel mechanism by which miR‑505‑3p inhibits bone metastasis of PCa, supporting the notion that miR‑505‑3p may serve as a predictive marker for bone metastasis of PCa.
View Figures
View References

Related Articles

Journal Cover

January-2019
Volume 41 Issue 1

Print ISSN: 1021-335X
Online ISSN:1791-2431

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Tang Y, Wu B, Huang S, Peng X, Li X, Huang X, Zhou W, Xie P and He P: Downregulation of miR‑505‑3p predicts poor bone metastasis‑free survival in prostate cancer. Oncol Rep 41: 57-66, 2019.
APA
Tang, Y., Wu, B., Huang, S., Peng, X., Li, X., Huang, X. ... He, P. (2019). Downregulation of miR‑505‑3p predicts poor bone metastasis‑free survival in prostate cancer. Oncology Reports, 41, 57-66. https://doi.org/10.3892/or.2018.6826
MLA
Tang, Y., Wu, B., Huang, S., Peng, X., Li, X., Huang, X., Zhou, W., Xie, P., He, P."Downregulation of miR‑505‑3p predicts poor bone metastasis‑free survival in prostate cancer". Oncology Reports 41.1 (2019): 57-66.
Chicago
Tang, Y., Wu, B., Huang, S., Peng, X., Li, X., Huang, X., Zhou, W., Xie, P., He, P."Downregulation of miR‑505‑3p predicts poor bone metastasis‑free survival in prostate cancer". Oncology Reports 41, no. 1 (2019): 57-66. https://doi.org/10.3892/or.2018.6826